Interaksi Esitalopram

Esitalopram (Lexapro), golongan SSRI, memiliki 349 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 119 mayor, 189 moderat, 38 minor, dan 3 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Esitalopram adalah antidepresan SSRI yang dijual sebagai Lexapro dan secara luas sebagai obat generik. Obat ini adalah bentuk tunggal aktif dari obat yang lebih lama, sitalopram, dan menaikkan jumlah serotonin yang tersedia di otak. Obat ini disetujui untuk depresi mayor pada orang berusia 12 tahun ke atas dan gangguan cemas menyeluruh pada orang berusia 7 tahun ke atas. Obat ini tersedia sebagai tablet dan biasanya diminum sekali sehari, pagi atau malam, dengan atau tanpa makanan.

Interaksi dari label

Interaksi mayor (119)

  • AlkoholAlkoholMayor

    Alcohol Prevention or Management Concomitant use of Escitalopram Capsules and alcohol is not recommended. (label Esitalopram, Interaksi obat)

  • AlmotriptantriptanMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Amfetaminstimulan SSPMayor

    Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (label Amfetamin, Peringatan dan perhatian)

  • Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (label Amfetamin dan dekstroamfetamin, Peringatan dan perhatian)

  • AmiodaronantiaritmiaMayor

    Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (label Amiodaron, Peringatan dan perhatian)

  • Amitriptilinantidepresan trisiklikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Amoksapinantidepresan trisiklikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Azitromisinantibiotik makrolidaMayor

    This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (label Azitromisin, Peringatan dan perhatian)

  • • Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Beladona dan opium, Interaksi obat)

  • Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • BuprenorfinopioidMayor

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Buprenorfin, Interaksi obat)

  • Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Buprenorfin dan nalokson, Interaksi obat)

  • Buspironobat serotonergikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Butalbital, aspirin, kafein, dan kodein, Interaksi obat)

  • • Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Butalbital, parasetamol, kafein, dan kodein, Interaksi obat)

  • ButorfanolopioidMayor

    …medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Butorfanol, Perhatian)

  • Dekstroamfetaminstimulan SSPMayor

    Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (label Dekstroamfetamin, Interaksi obat)

  • Dekstrometorfanobat serotonergikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Dekstrometorfan dan kuinidinobat serotonergikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Desipraminantidepresan trisiklikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Dihidroergotaminalkaloid ergotMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • DofetilidantiaritmiaMayor

    Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (label Dofetilid, Peringatan)

  • Doksepinantidepresan trisiklikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • DronedaronantiaritmiaMayor

    …(12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone • QTc interval >500 ms or… (label Dronedaron, Kontraindikasi)

  • DuloksetinSNRIMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • EdoksabanantikoagulanMayor

    Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding. (label Edoksaban, Interaksi obat)

  • EletriptantriptanMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (label Emtrisitabin, rilpivirin, dan tenofovir, Peringatan dan perhatian)

  • Fenelzinpenghambat MAOMayor

    Escitalopram Capsules are contraindicated in patients: Taking, or within 14 days of stopping, MAOIs, including linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.6 ), Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )] . (label Esitalopram, Kontraindikasi)

  • FenobarbitalbarbituratMayor

    Drugs that Prolong the QT Interval : Avoid concomitant use. (label Fenobarbital, Interaksi obat)

  • FentanilopioidMayor

    • Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (label Fentanil, Peringatan dan perhatian)

  • Flibanserindepresan SSPMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Flukonazolantijamur azolMayor

    Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (label Flukonazol, Kontraindikasi)

  • FlumazenilbenzodiazepinMayor

    THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. (label Flumazenil, Peringatan kotak hitam)

  • FluoksetinSSRIMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • FluvoksaminSSRIMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • FosfomisinantibiotikMayor

    Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (label Fosfomisin, Interaksi obat)

  • FoskarnetantivirusMayor

    (See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (label Foskarnet, Interaksi obat)

  • FrovatriptantriptanMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Granisetronobat yang memperpanjang interval QTMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • HidrokodonopioidMayor

    Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Hidrokodon, Interaksi obat)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Hidrokodon dan homatropin, Interaksi obat)

  • S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Hidrokodon dan ibuprofen, Perhatian)

  • Serotonergic drugs : Concomitant use may result in serotonin syndrome. (label Hidrokodon dan klorfeniramin, Interaksi obat)

  • Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Hidrokodon dan parasetamol, Perhatian)

  • Hidroksiklorokuinobat yang memperpanjang interval QTMayor

    Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

  • HidromorfonopioidMayor

    • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Hidromorfon, Interaksi obat)

  • IloperidonantipsikotikMayor

    Avoid the use of FANAPT in combination with any other drugs that prolong the QT interval [see Warnings and Precautions (5.3) ] . (label Iloperidon, Interaksi obat)

  • Imipraminantidepresan trisiklikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • IsoniazidantibiotikMayor

    Escitalopram Capsules are contraindicated in patients: Taking, or within 14 days of stopping, MAOIs, including linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.6 ), Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )] . (label Esitalopram, Kontraindikasi)

  • Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (label Ivabradin, Peringatan dan perhatian)

  • KarbamazepinantikonvulsanMayor

    Known hypersensitivity to tricyclic antidepressants ( 4 ) (label Karbamazepin, Kontraindikasi)

  • Klomipraminantidepresan trisiklikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • KodeinopioidMayor

    • Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Kodein, Interaksi obat)

  • LevofloksasinfluorokuinolonMayor

    Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (label Levofloksasin, Peringatan dan perhatian)

  • Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • LevorfanolopioidMayor

    Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Levorfanol, Perhatian)

  • LinezolidantibiotikMayor

    Escitalopram Capsules are contraindicated in patients: Taking, or within 14 days of stopping, MAOIs, including linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.6 ), Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )] . (label Esitalopram, Kontraindikasi)

  • Lisdeksamfetaminstimulan SSPMayor

    Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (label Lisdeksamfetamin, Peringatan dan perhatian)

  • Litiumobat serotonergikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Lopinavir dan ritonavirantiretroviralMayor

    Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (label Lopinavir dan ritonavir, Peringatan dan perhatian)

  • LorazepambenzodiazepinMayor

    LOREEV XR should not be used in such patients without adequate antidepressant therapy. (label Lorazepam, Peringatan dan perhatian)

  • MetadonopioidMayor

    Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (label Metadon, Peringatan dan perhatian)

  • Metaksalonpelemas ototMayor

    Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (label Metaksalon, Interaksi obat)

  • Metamfetaminstimulan SSPMayor

    Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (label Metamfetamin, Peringatan dan perhatian)

  • Metilen birupenghambat MAOMayor

    Escitalopram Capsules are contraindicated in patients: Taking, or within 14 days of stopping, MAOIs, including linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.6 ), Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )] . (label Esitalopram, Kontraindikasi)

  • MilnasipranSNRIMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • MirtazapinantidepresanMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • MorfinopioidMayor

    • Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Morfin, Interaksi obat)

  • NaratriptantriptanMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • NefazodonantidepresanMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Nortriptilinantidepresan trisiklikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (label Oksaliplatin, Interaksi obat)

  • OksikodonopioidMayor

    Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (label Oksikodon, Interaksi obat)

  • OksimorfonopioidMayor

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Oksimorfon, Interaksi obat)

  • Olanzapin dan fluoksetinantipsikotikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • OliseridinopioidMayor

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Oliseridin, Interaksi obat)

  • Ondansetronobat yang memperpanjang interval QTMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Palonosetronobat serotonergikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Parasetamol dan kodein, Perhatian)

  • ParoksetinSSRIMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Pentazosin dan nalokson, Perhatian)

  • PetidinopioidMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • PimozidantipsikotikMayor

    Taking pimozide because of the risk of QT prolongation [see Drug Interactions ( 7 )] . (label Esitalopram, Kontraindikasi)

  • Pitolisantobat yang memperpanjang interval QTMayor

    The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (label Pitolisant, Peringatan dan perhatian)

  • PrometazinantihistaminMayor

    …prolong, or intensify the sedative action of other central-nervous-system depressants, such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine HCl. (label Prometazin, Interaksi obat)

  • Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Prometazin dan kodein, Interaksi obat)

  • PropafenonantiaritmiaMayor

    • Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (label Propafenon, Peringatan dan perhatian)

  • Protriptilinantidepresan trisiklikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Prukalopridobat serotonergikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Rasagilinpenghambat MAOMayor

    Escitalopram Capsules are contraindicated in patients: Taking, or within 14 days of stopping, MAOIs, including linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.6 ), Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )] . (label Esitalopram, Kontraindikasi)

  • RemifentanilopioidMayor

    • Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (label Remifentanil, Peringatan dan perhatian)

  • RizatriptantriptanMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Selegilinpenghambat MAOMayor

    Escitalopram Capsules are contraindicated in patients: Taking, or within 14 days of stopping, MAOIs, including linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.6 ), Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )] . (label Esitalopram, Kontraindikasi)

  • SertralinSSRIMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Siklobenzaprinpelemas ototMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • SiprofloksasinfluorokuinolonMayor

    Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (label Siprofloksasin, Peringatan dan perhatian)

  • SitalopramSSRIMayor

    With known hypersensitivity to escitalopram or citalopram or any of the inactive ingredients in Escitalopram Capsules. (label Esitalopram, Kontraindikasi)

  • Solriamfetolstimulan SSPMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • St. John's wortHerbal dan suplemenMayor

    Mengombinasikan St. John's wort dengan antidepresan dan obat serotonergik lain meningkatkan risiko sindrom serotonin. (NCCIH, St. John's Wort)

  • SumatriptantriptanMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • TapentadolopioidMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Tetrabenazinpenghambat VMAT2Mayor

    Certain conditions may increase the risk for torsade de pointes or sudden death such as (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval [see Warnings and Precautions ( 5.8 ), Clinical Pharmacology (12.2) ]. (label Tetrabenazin, Interaksi obat)

  • TioridazinantipsikotikMayor

    CONTRAINDICATIONS Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias. (label Tioridazin, Kontraindikasi)

  • TramadolopioidMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Tranilsiprominpenghambat MAOMayor

    Escitalopram Capsules are contraindicated in patients: Taking, or within 14 days of stopping, MAOIs, including linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.6 ), Warnings and Precautions ( 5.2 ), Drug Interactions ( 7 )] . (label Esitalopram, Kontraindikasi)

  • TrazodonantidepresanMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Trimipraminantidepresan trisiklikMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • VenlafaksinSNRIMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (label Vepdegestrant, Peringatan dan perhatian)

  • VilazodonSSRIMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • VortioksetinantidepresanMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

  • ZiprasidonantipsikotikMayor

    …drugs, ziprasidone is contraindicated: • in patients with a known history of QT prolongation (including congenital long QT syndrome) • in patients with recent acute myocardial infarction • in patients with uncompensated heart failure Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. (label Ziprasidon, Kontraindikasi)

  • ZolmitriptantriptanMayor

    Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (label Esitalopram, Peringatan dan perhatian)

Interaksi moderat (189)

  • Amiloriddiuretik hemat kaliumModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Anagrelidobat yang memperpanjang interval QTModerat

    Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (label Anagrelid, Peringatan dan perhatian)

  • ApiksabanantikoagulanModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Arformoterolagonis beta-adrenergikModerat

    MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (label Arformoterol, Interaksi obat)

  • ArgatrobanantikoagulanModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Armodafinilstimulan SSPModerat

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (label Esitalopram, Peringatan dan perhatian)

  • Artikain dan epinefrinanestetik lokalModerat

    The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (label Artikain dan epinefrin, Interaksi obat)

  • Asam etakrinatdiuretik loopModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Asam mefenamatOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Asetazolamidpenghambat karbonat anhidraseModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • AspirinOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Aspirin dan dipiridamolantiplateletModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Atenolol dan klortalidonpenyekat betaModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Benazepril dan hidroklorotiazidpenghambat ACEModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Benzfetaminstimulan SSPModerat

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (label Esitalopram, Peringatan dan perhatian)

  • Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (label Bismut subsitrat, metronidazol, dan tetrasiklin, Peringatan dan perhatian)

  • Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • BivalirudinantikoagulanModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Brimonidinagonis alfa-adrenergikModerat

    Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (label Brimonidin, Interaksi obat)

  • Brimonidin dan timololagonis alfa-adrenergikModerat

    CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (label Brimonidin dan timolol, Interaksi obat)

  • Budesonid dan formoterolkortikosteroidModerat

    Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (label Budesonid dan formoterol, Interaksi obat)

  • Bumetaniddiuretik loopModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Bupivakainanestetik lokalModerat

    …Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (label Bupivakain, Peringatan dan perhatian)

  • Bupivakain dan epinefrinanestetik lokalModerat

    …Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (label Bupivakain dan epinefrin, Peringatan dan perhatian)

  • BupropionantidepresanModerat

    …hydrochloride extended-release tablets (XL), concurrent administration of bupropion hydrochloride extended-release tablets (XL) and agents that lower the seizure threshold (e.g., other bupropion products, antipsychotics, antidepressants, theophylline, or systemic corticosteroids) should be undertaken only with extreme caution [see Warnings and Precautions (5.3)] . (label Bupropion, Interaksi obat)

  • Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (label Esitalopram, Peringatan dan perhatian)

  • DabigatranantikoagulanModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Daridoreksantsedatif-hipnotikModerat

    Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (label Daridoreksant, Peringatan dan perhatian)

  • DarifenasinantikolinergikModerat

    Caution should be taken when darifenacin extended-release tablets is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants ( 7.2 ) (label Darifenasin, Interaksi obat)

  • DarunavirantiretroviralModerat

    Antidepressants : Selective Serotonin Reuptake Inhibitors (SSRIs): paroxetine, sertraline ↓ paroxetine ↓ sertraline If either sertraline or paroxetine is initiated in patients receiving PREZISTA/ritonavir, dose titrating the SSRI based on a clinical assessment of antidepressant response is recommended. (label Darunavir, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralModerat

    Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs): e.g. paroxetine, sertraline SSRIs: effects unknown When co-administering with SSRIs, TCAs, or trazodone, careful dose titration of the antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitoring for antidepressant response are recommended. (label Darunavir dan kobisistat, Interaksi obat)

  • Deksmetilfenidatstimulan SSPModerat

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (label Esitalopram, Peringatan dan perhatian)

  • Desflurananestetik umumModerat

    Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (label Desfluran, Peringatan dan perhatian)

  • …that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin… (label Desmopresin, Interaksi obat)

  • DiazepambenzodiazepinModerat

    …be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. (label Diazepam, Interaksi obat)

  • Dietilpropionstimulan SSPModerat

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (label Esitalopram, Peringatan dan perhatian)

  • DiflunisalOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • DiklofenakOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • DipiridamolantiplateletModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • DisikloverinantikolinergikModerat

    …drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (label Disikloverin, Interaksi obat)

  • Dorzolamid dan timololpenghambat karbonat anhidraseModerat

    CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (label Dorzolamid dan timolol, Interaksi obat)

  • DronabinolkanabinoidModerat

    Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (label Dronabinol, Peringatan dan perhatian)

  • Droperidolantagonis dopaminModerat

    …cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs… (label Droperidol, Peringatan)

  • EfavirenzantiretroviralModerat

    QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between efavirenz and drugs that prolong the QTc interval. (label Efavirenz, Interaksi obat)

  • QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between EFV and drugs that prolong the QTc interval. (label Efavirenz, lamivudin, dan tenofovir, Interaksi obat)

  • Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs) e.g., paroxetine Tricyclic Antidepressants (TCAs) e.g., amitriptyline desipramine imipramine nortriptyline bupropion trazodone ↑ SSRIs (except sertraline) ↑ TCAs ↑ trazodone Careful dosage titration of the antidepressant and monitoring for antidepressant response are recommended when coadministered… (label Elvitegravir, kobisistat, emtrisitabin, dan tenofovir, Interaksi obat)

  • Enalapril dan hidroklorotiazidpenghambat ACEModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • EnoksaparinantikoagulanModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • EpinefrinsimpatomimetikModerat

    • Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (label Epinefrin, Interaksi obat)

  • Eplerenonantagonis aldosteronModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • EptifibatidantiplateletModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Ergotamin dan kafeinalkaloid ergotModerat

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (label Esitalopram, Peringatan dan perhatian)

  • EribulinModerat

    QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (label Eribulin, Peringatan dan perhatian)

  • Eszopiklonsedatif-hipnotikModerat

    Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (label Eszopiklon, Peringatan dan perhatian)

  • EtodolakOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Fendimetrazinstimulan SSPModerat

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (label Esitalopram, Peringatan dan perhatian)

  • FenilefrindekongestanModerat

    Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (label Fenilefrin, Interaksi obat)

  • FenitoinantikonvulsanModerat

    …Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (label Fenitoin, Interaksi obat)

  • FenoprofenOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Fenterminstimulan SSPModerat

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (label Esitalopram, Peringatan dan perhatian)

  • Fentermin dan topiramatstimulan SSPModerat

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (label Esitalopram, Peringatan dan perhatian)

  • Fisostigminpenghambat kolinesteraseModerat

    Acute cardiac arrest may be possible during treatment with tricyclic antidepressants; therefore, Anticholium should only be considered as an antidote for this indication while the patient has continuous ECG monitoring. (label Fisostigmin, Peringatan dan perhatian)

  • FlurbiprofenOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Flutikason dan salmeterolkortikosteroidModerat

    Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (label Flutikason dan salmeterol, Interaksi obat)

  • FondaparinuksantikoagulanModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Formoterolagonis beta-adrenergikModerat

    • MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (label Formoterol, Interaksi obat)

  • FosamprenavirantiretroviralModerat

    Antidepressant: Paroxetine, trazodone ↓ Paroxetine Any paroxetine dose adjustment should be guided by clinical effect (tolerability and efficacy). ↑ Trazodone Adverse events of nausea, dizziness, hypotension, and syncope have been observed following coadministration of trazodone and ritonavir. (label Fosamprenavir, Interaksi obat)

  • FosfenitoinantikonvulsanModerat

    …Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (label Fosfenitoin, Interaksi obat)

  • Fosinopril dan hidroklorotiazidpenghambat ACEModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Furosemiddiuretik loopModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • GefitinibModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • GlikopironiumantikolinergikModerat

    Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (label Glikopironium, Interaksi obat)

  • GoserelinModerat

    Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (label Goserelin, Peringatan dan perhatian)

  • HaloperidolantipsikotikModerat

    Plasma concentrations of CYP2D6 substrates (e,g. tricyclic antidepressants such as desipramine or imipramine) may increase when they are co-administered with haloperidol. (label Haloperidol, Interaksi obat)

  • HeparinantikoagulanModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Hidroklorotiaziddiuretik tiazidModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • IbuprofenOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Indapamiddiuretik tiazidModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • IndometasinOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Ipratropium dan salbutamolantikolinergikModerat

    Monoamine Oxidase Inhibitors or Tricyclic Antidepressants Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of albuterol sulfate on the cardiovascular… (label Ipratropium dan salbutamol, Interaksi obat)

  • Irbesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Isoflurananestetik umumModerat

    Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (label Isofluran, Peringatan dan perhatian)

  • Isoprenalinagonis beta-adrenergikModerat

    Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (label Isoprenalin, Interaksi obat)

  • Itrakonazolantijamur azolModerat

    SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions. (label Itrakonazol, Interaksi obat)

  • Kandesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • KangrelorantiplateletModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Karbidopa, levodopa, dan entakaponobat dopaminergikModerat

    • Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (label Karbidopa, levodopa, dan entakapon, Interaksi obat)

  • Karisoprodolpelemas ototModerat

    Since the sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously. (label Karisoprodol, Peringatan dan perhatian)

  • KetoprofenOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • KetorolakOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • KlonazepambenzodiazepinModerat

    …Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (label Klonazepam, Interaksi obat)

  • Klonidinagonis alfa-adrenergikModerat

    Tricyclic antidepressants Clinical Implication Concomitant use of tricyclic antidepressants with clonidine can increase blood pressure and may counteract the hypotensive effects of clonidine. (label Klonidin, Interaksi obat)

  • KlopidogrelantiplateletModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • KlorazepatbenzodiazepinModerat

    The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (label Klorazepat, Interaksi obat)

  • Kloroprokainanestetik lokalModerat

    Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (label Kloroprokain, Perhatian)

  • Klorotiaziddiuretik tiazidModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Klortalidondiuretik tiazidModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • KlozapinantipsikotikModerat

    CYP2D6 and CYP3A4 Inhibitors Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology ( 12.3 )] . (label Klozapin, Interaksi obat)

  • Kokainanestetik lokalModerat

    Sympathomimetics, postganglionic blocking agents, and tricyclic antidepressants: Concomitant administration may increase the risk of cardiovascular adverse reactions. (label Kokain, Interaksi obat)

  • KuetiapinantipsikotikModerat

    It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. (label Kuetiapin, Peringatan dan perhatian)

  • Kuinapril dan hidroklorotiazidpenghambat ACEModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Lapatinibpenghambat P-glikoproteinModerat

    TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

  • Lemboreksantsedatif-hipnotikModerat

    Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (label Lemboreksant, Peringatan dan perhatian)

  • Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (label Leuprorelin, Peringatan dan perhatian)

  • Levosalbutamolagonis beta-adrenergikModerat

    Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (label Levosalbutamol, Interaksi obat)

  • Levotiroksinhormon tiroidModerat

    Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (label Levotiroksin, Interaksi obat)

  • Lidokainanestetik lokalModerat

    Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (label Lidokain, Interaksi obat)

  • Lidokain dan epinefrinanestetik lokalModerat

    …Adverse Reactions Due to Drug Interactions with FLAVALTA Risk of Severe, Persistent Hypertension Due to Drug Interactions Between FLAVALTA and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants may result… (label Lidokain dan epinefrin, Peringatan dan perhatian)

  • Liotironinhormon tiroidModerat

    Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and liothyronine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (label Liotironin, Interaksi obat)

  • Lisinopril dan hidroklorotiazidpenghambat ACEModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Lofeksidinagonis alfa-adrenergikModerat

    Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (label Lofeksidin, Peringatan dan perhatian)

  • Losartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • LumateperonantipsikotikModerat

    Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (label Lumateperon, Peringatan dan perhatian)

  • LurasidonantipsikotikModerat

    Activation of Mania/Hypomania Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. (label Lurasidon, Peringatan dan perhatian)

  • MeflokuinantimalariaModerat

    Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (label Meflokuin, Interaksi obat)

  • MeloksikamOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Mepivakainanestetik lokalModerat

    Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (label Mepivakain, Peringatan)

  • Metilfenidatstimulan SSPModerat

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (label Esitalopram, Peringatan dan perhatian)

  • Metolazondiuretik tiazidModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • MetronidazolantibiotikModerat

    Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (label Metronidazol, Interaksi obat)

  • MetskopolaminantikolinergikModerat

    Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (label Metskopolamin, Interaksi obat)

  • Mifepristonpenghambat CYP3A4Moderat

    There is little or no experience with high exposure, concomitant dosing with other QT-prolonging drugs, or potassium channel variants resulting in a long QT interval. [See Warnings & Precautions ( 5.6 )] To minimize risk, the lowest effective dose should always be used. (label Mifepriston, Peringatan dan perhatian)

  • Modafinilstimulan SSPModerat

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (label Esitalopram, Peringatan dan perhatian)

  • MoksifloksasinfluorokuinolonModerat

    Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (label Moksifloksasin, Peringatan dan perhatian)

  • NabumetonOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • NalbufinopioidModerat

    Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (label Nalbufin, Interaksi obat)

  • Naltrekson dan bupropionantagonis opioidModerat

    Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of antidepressants, (e.g., selective serotonin reuptake inhibitors and many tricyclics), antipsychotics (e.g., haloperidol, risperidone and thioridazine), beta-blockers (e.g., metoprolol) and Type 1C antiarrhythmics (e.g., propafenone and flecainide). (label Naltrekson dan bupropion, Interaksi obat)

  • NaproksenOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Natrium oksibatdepresan SSPModerat

    The concurrent use of Xyrem with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and… (label Natrium oksibat, Peringatan dan perhatian)

  • Antidepressants bupropion ↓ bupropion and active metabolite hydroxy-bupropion Monitor for an adequate clinical response to bupropion. trazodone ↑ trazodone Adverse reactions of nausea, dizziness, hypotension, and syncope have been observed following co-administration of trazodone and ritonavir. (label Nirmatrelvir dan ritonavir, Interaksi obat)

  • OksaprozinOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Olmesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • PaliperidonantipsikotikModerat

    …combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. (label Paliperidon, Peringatan dan perhatian)

  • Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • PasireotidModerat

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

  • PiroksikamOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • PonesimodimunosupresanModerat

    Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (label Ponesimod, Interaksi obat)

  • PrasugrelantiplateletModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Prilokain dan epinefrinanestetik lokalModerat

    …Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (label Prilokain dan epinefrin, Interaksi obat)

  • PrimakuinantimalariaModerat

    QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (label Primakuin, Interaksi obat)

  • Ranolazinobat yang memperpanjang interval QTModerat

    Drugs transported by P-gp (e.g., digoxin), or drugs metabolized by CYP2D6 (e.g., tricyclic antidepressants) may need reduced doses when used with ASPRUZYO Sprinkle. (label Ranolazin, Interaksi obat)

  • RifampisinantibiotikModerat

    …5-HT 3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline A tuberculosis treatment regimen including rifampin (600 mg/day), isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day), and pyridoxine (25 mg) was… (label Rifampisin, Interaksi obat)

  • RifapentinantibiotikModerat

    …levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (label Rifapentin, Interaksi obat)

  • RilpivirinantiretroviralModerat

    In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (label Rilpivirin, Peringatan dan perhatian)

  • RitonavirantiretroviralModerat

    Antidepressants: nefazodone, selective serotonin reuptake inhibitors (SSRIs): e.g. fluoxetine, paroxetine, tricyclics: e.g. amitriptyline, nortriptyline ↑ antidepressants A dose decrease may be needed for these drugs when co-administered with ritonavir. (label Ritonavir, Interaksi obat)

  • RivaroksabanantikoagulanModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Rokuroniumpenyekat neuromuskularModerat

    QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (label Rokuronium, Peringatan dan perhatian)

  • Salbutamolagonis beta-adrenergikModerat

    Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (label Salbutamol, Interaksi obat)

  • Salmeterolagonis beta-adrenergikModerat

    • Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (label Salmeterol, Interaksi obat)

  • SalsalatOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • SelekoksibOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Sevoflurananestetik umumModerat

    Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (label Sevofluran, Peringatan)

  • SilostazolantiplateletModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Simetidinpenghambat H2Moderat

    …apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline, and metronidazole, thereby delaying elimination and increasing blood levels of these drugs. (label Simetidin, Interaksi obat)

  • Sinakalsetpenghambat CYP2D6Moderat

    QT Interval Prolongation and V entricular A rr h ythmia Decreases in serum calcium can also prolong the QT interval, potentially resulting in ventricular arrhythmia. (label Sinakalset, Peringatan dan perhatian)

  • SkopolaminantikolinergikModerat

    Concomitant use of other drugs that cause central nervous system (CNS) adverse reactions (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may increase this effect [see Drug Interactions ( 7.1 )] . (label Skopolamin, Peringatan dan perhatian)

  • SorafenibModerat

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

  • Sotalolpenyekat betaModerat

    Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (label Sotalol, Interaksi obat)

  • Spironolaktonantagonis aldosteronModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Spironolakton dan hidroklorotiazidantagonis aldosteronModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. (label Sulfametoksazol dan trimetoprim (kotrimoksazol), Interaksi obat)

  • SulindakOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • SunitinibModerat

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

  • Suvoreksantsedatif-hipnotikModerat

    Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Suvoreksant, Peringatan dan perhatian)

  • Telmisartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • TemazepambenzodiazepinModerat

    The benzodiazepines, including temazepam, produce additive CNS-depressant effects when co-administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. (label Temazepam, Interaksi obat)

  • Terbutalinagonis beta-adrenergikModerat

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (label Terbutalin, Perhatian)

  • TikagrelorantiplateletModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • TirofibanantiplateletModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Tizanidinpelemas ototModerat

    The CNS depressant effects of Zanaflex with alcohol and other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants) may be additive [see Drug Interactions ( 7.4 )] . (label Tizanidin, Peringatan dan perhatian)

  • TolmetinOAINSModerat

    Increased Risk of Bleeding: Concomitant use of nonsteroidal anti-inflammatory drugs, aspirin, other antiplatelet drugs, warfarin and other anticoagulants may increase risk ( 5.7 , 7) (label Esitalopram, Peringatan dan perhatian)

  • Torasemiddiuretik loopModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Toremifenmodulator reseptor estrogen selektifModerat

    …quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). (label Toremifen, Interaksi obat)

  • Triamterendiuretik hemat kaliumModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Triamteren dan hidroklorotiaziddiuretik hemat kaliumModerat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (label Triptorelin, Peringatan dan perhatian)

  • Umeklidinium dan vilanterolantikolinergikModerat

    • Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (label Umeklidinium dan vilanterol, Interaksi obat)

  • Valsartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

  • VasopresinModerat

    Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (label Vasopresin, Interaksi obat)

  • WarfarinantikoagulanModerat

    For patients taking warfarin, carefully monitor the international normalized ratio [see Drug Interactions ( 7 )] . (label Esitalopram, Peringatan dan perhatian)

  • Zaleplonsedatif-hipnotikModerat

    Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (label Zaleplon, Peringatan)

  • Zolpidemsedatif-hipnotikModerat

    Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use [see Drug Interactions (7.1) ] . (label Zolpidem, Peringatan dan perhatian)

Penyebutan minor (38)

  • Asam valproatantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • AtazanavirantiretroviralMinor

    Antidepressants: tricyclic antidepressants ↑ tricyclic antidepressants Coadministration with REYATAZ has the potential to produce serious and/or life-threatening adverse events and has not been studied. (label Atazanavir, Interaksi obat)

  • BenztropinantikolinergikMinor

    Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants. (label Benztropin, Peringatan)

  • BrekspiprazolantipsikotikMinor

    However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (label Brekspiprazol, Peringatan dan perhatian)

  • BrivarasetamantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • Divalproeks (valproat)antikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • EluksadolinopioidMinor

    Mechanism and Clinical Effect(s) Concomitant use of Escitalopram Capsules and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (label Esitalopram, Interaksi obat)

  • EslikarbazepinantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • EtosuksimidantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • FelbamatantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • GabapentinantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • HidroksizinantihistaminMinor

    …quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone,… (label Hidroksizin, Perhatian)

  • Kanabidiol (obat resep)antikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations. (label Karbidopa, Interaksi obat)

  • KariprazinantipsikotikMinor

    …placebo-controlled trials of adult patients with major depressive disorder, the proportion of patients with shifts in fasting glucose from normal (<100 mg/dL) to high (≥126 mg/dL) was greatest in the VRAYLAR 3 mg per day + antidepressant therapy arm (3.2%) compared with those taking VRAYLAR 1.5 mg per day + antidepressant therapy (2%) or those placebo-treated (1.3%). (label Kariprazin, Peringatan dan perhatian)

  • KlobazambenzodiazepinMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • KuinidinantiaritmiaMinor

    Cytochrome P450 IID6 is an enzyme critical to the metabolism of many drugs, notably including mexiletine , some phenothiazines , and most polycyclic antidepressants . (label Kuinidin, Interaksi obat)

  • LakosamidantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • LamotriginantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • LevetirasetamantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • LovastatinstatinMinor

    These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (label Lovastatin, Peringatan)

  • MetsuksimidantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • Mechanism and Clinical Effect(s) Concomitant use of Escitalopram Capsules and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (label Esitalopram, Interaksi obat)

  • OkskarbazepinantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • PerampanelantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • PerfenazinantipsikotikMinor

    Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (label Perfenazin, Interaksi obat)

  • PregabalinantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • PrimidonantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • Propranololpenyekat betaMinor

    Antidepressants: The hypotensive effect of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers. (label Propranolol, Interaksi obat)

  • RufinamidantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • SenobamatantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • TerbinafinantijamurMinor

    Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (label Terbinafin, Interaksi obat)

  • TiagabinantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • It is difficult to determine if Tolcapone tablets played a role in the pathogenesis of these events because these patients received several concomitant medications affecting the central nervous system such as monoaminergic (i.e., MAO-I, tricyclic and selective serotonin reuptake inhibitors) and anticholinergic agents. (label Tolkapon, Perhatian)

  • TopiramatantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • TriheksifenidilantikolinergikMinor

    Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

  • VigabatrinantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

  • ZonisamidantikonvulsanMinor

    Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Escitalopram Capsules have not been systematically evaluated in patients with a seizure disorder. (label Esitalopram, Peringatan dan perhatian)

Tidak ada interaksi bermakna yang dilaporkan (3)

  • DesloratadinantihistaminTanpa interaksi

    …changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .] 7.2 Fluoxetine In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes… (label Desloratadin, Interaksi obat)

  • EntakaponTanpa interaksi

    No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa and dopa-decarboxylase inhibitor. (label Entakapon, Perhatian)

  • Ropinirolagonis dopaminTanpa interaksi

    Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (label Ropinirol, Interaksi obat)

Periksa Esitalopram terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.